A Phase 1 interventional study of MTX-463 and Placebo in Healthy Adult Male, sponsored by Mediar Therapeutics. Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by Mediar Therapeutics · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, and PK of MTX-463 when administered via SC injection in healthy adult males.
This is a randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, and PK of MTX-463 when administered via SC injection in healthy adult males. The study will consist of a single cohort comprising 8 healthy male participants, who on Day 1 will be randomly assigned to receive MTX-463 or matched placebo. Randomization will be in a 3:1 ratio such that 6 participants will receive MTX-463 and 2 will receive placebo. Participants randomized to MTX-463 will receive a dose of 250 mg of MTX-463.
Participants randomized to placebo will receive SC injections containing sodium chloride 0.9%. The injections will be given under the skin of the abdominal wall on Day 1. Blood will be drawn pre-dose on Day 1 for PK and antidrug antibodies (ADAs) and post-dose for PK at 6 and 24 hours. Participants will remain in the clinical research unit (CRU) for 24 hours after their injections, and then they will return for outpatient PK blood draws on Days 3 through 8, 15, and 22, with blood drawn for ADA assessment on Days 15 and 22. Each participant will undergo assessments at specified timepoints on Days 1 through 22 as detailed in Table 1. End-of-study procedures will be completed on Day 22 or upon early termination (ET). Local safety and tolerability at the injection site will be assessed at the time of the injections and for 24 hours afterward, and on Days 5, 8, 15 (±1 day), and 22 (±2 days) (EOS/ET).
Mediar Therapeutics is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MTX-463
Biological: MTX-463
Placebo
Other: Placebo
MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases, including IPF, and malignancies.
Placebo
PK will be evaluated by area under the plasma concentration versus time curve from time zero to t (AUC0-t) of MTX-463
Unit of Measure: Nanogram·hour per milliliter (ng·h/mL)
Time frame: 22 Days
PK will be evaluated by Maximum Observed Plasma Concentration (Cmax) of MTX-463
Unit of measure: ng/mL
Time frame: 22 Days
Comparisons of Maximum Observed Plasma Concentration (Cmax) of MTX-463 will be made to historical single-dose 4-mg/kg IV data.
Unit of measure: ng/mL
Time frame: 22 Days
Comparisons of area under the plasma concentration versus time curve from time zero to t (AUC0-t) of MTX-463 will be made to historical single-dose 4-mg/kg IV data.
Unit of Measure: Nanogram·hour per milliliter (ng·h/mL)
Time frame: 22 Days
Incidence of serious adverse events (SAEs)
Number SAEs as defined by protocol criteria
Time frame: 22 days
Incidence of Treatment Emergent Adverse Events (TEAEs)
Number of TEAEs summarized by seriousness and maximum severity as defined by protocol criteria
Time frame: 22 days
Incidence of Treatment Related Adverse Events (TRAEs)
Number of TRAEs summarized by seriousness and maximum severity as defined by Protocol criteria
Time frame: 22 days
Clinically significant findings on clinical laboratory tests
Clinically significant findings in hematology, clinical chemistry, urinalysis, and other protocol-specified laboratory parameters will be summarized. Units of Measure: Standard laboratory units (e.g., g/dL, mEq/L, mg/dL, increase by factor)
Time frame: 22 days
Descriptive statistics on vital signs.
Descriptive statistics on temperature (Units: degrees Celcius), pulse rate (Units: beats per minute), respiratory rate (Units: breaths per minute), and blood pressure (Units: mmHg) will be assessed for change from Baseline, when applicable, and summarized by timepoint.
Time frame: 22 Days
Descriptive statistics on electrocardiograms (ECGs)
Descriptive statistics on ECG parameters (including but not limited to PR interval, QRS interval, QT, QTcF, and RR) will be assessed for change from Baseline, when applicable, and summarized by timepoint. Units: msec
Time frame: 22 Days
Descriptive statistics on clinical laboratory tests.
Descriptive statistics on hematology, clinical chemistry, urinalysis, and other protocol-specified laboratory parameters will be assessed for change from Baseline, when applicable, and summarized by timepoint. Units of Measure: Standard laboratory units (e.g., g/dL, mEq/L, mg/dL, increase by factor)
Time frame: 22 Days
Incidence of injection site pain and injection site reactions
Number of incidents of injection site pain and injection site reactions as assessed by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (V2.1)
Time frame: 22 days
Presence of Anti-Drug Antibodies (ADA)
Presence of ADAs against MTX-463 in serum as assessed by a validated ELICA assay.
Time frame: 22 days
Signal inhibition in the confirmatory assay of Anti-Drug Antibodies (ADA)
Signal inhibition in the confirmatory assay of Anti-Drug Antibodies (ADA) to assess the frequency with which positive signals are confirmed.
Time frame: 22 days
Titer of Anti-Drug Antibodies (ADA)
Titer of ADAs against MTX-463 in serum as assessed by a validated ELICA assay. Units: titer units
Time frame: 22 days
Impact of Anti-Drug Antibodies (ADA)
To assess whether the presence of ADA impacts the concentration of MTX-463 and adverse events.
Time frame: 22 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Mar 2026, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MTX-463
Mediar Therapeutics